A History of Agilent Technologies MTA
The Story of an S&P 500 Company

About this book:

Agilent Technologies emerged in 1999 as a spin-off from Hewlett-Packard, inheriting a legacy of electronic test and measurement innovation dating back to the famous Palo Alto garage. Initially burdened by the dot-com bust, the company navigated early turbulence through aggressive cost management and a steadfast commitment to R&D. Under CEO Ned Barnholt, Agilent sharpened its strategic focus by divesting non-core assets—most notably its medical products group to Philips and its semiconductor products group to form Avago Technologies—effectively shedding cyclical, capital-intensive businesses to concentrate on the more stable, high-growth sectors of life sciences, diagnostics, and applied chemical analysis.

Strategic acquisitions became the primary engine for expanding capabilities and market leadership. The purchases of Varian, Inc. in 2010 and Dako A/S in 2012 were transformative, significantly bolstering Agilent's portfolio in atomic spectroscopy, mass spectrometry, and cancer diagnostics. These moves, combined with organic innovation in gas chromatography, liquid chromatography, and genomics workflow solutions (such as the SureSelect target enrichment system), allowed Agilent to offer comprehensive end-to-end workflows. The company solidified its dominance in chemical analysis and established a critical foothold in clinical diagnostics, particularly through companion diagnostics that enable personalized medicine.

Agilent's resilience was tested and proven during the 2008 financial crisis and the COVID-19 pandemic, where its focused portfolio provided stability and its instruments became essential tools for viral research, vaccine development, and diagnostic testing. The final major portfolio shift occurred in 2014 with the spin-off of the remaining electronic measurement business into Keysight Technologies, completing Agilent's transformation into a pure-play life sciences and diagnostics company. Today, under CEO Mike McMullen, Agilent operates as a financially robust S&P 500 leader with a global footprint, characterized by deep customer partnerships, a culture of innovation rooted in "The Agilent Way," and a strategic vision centered on precision medicine, spatial biology, and sustainable scientific advancement.

What You'll Find Inside:

• The dramatic spin-off from Hewlett-Packard in 1999 and how Agilent leveraged the legendary 'HP Way' culture to forge its own identity as a measurement-focused company.
• How Agilent survived the devastating dot-com bust through decisive cost management, protecting R&D investment, and pivoting toward more stable life sciences and chemical analysis markets.
• The strategic divestitures of the medical products group (to Philips) and semiconductor businesses (to Avago/Keysight) that sharpened Agilent's focus on high-growth, high-margin scientific instrumentation.
• Growth through landmark acquisitions like Varian (elemental analysis) and Dako (cancer diagnostics) that transformed Agilent into a life sciences, diagnostics, and applied chemical markets powerhouse.
• Agilent's evolution into a pure-play S&P 500 leader, driving innovations in mass spectrometry, chromatography, genomics workflows, and companion diagnostics that enable scientific breakthroughs and improve human health.

Who's It For:

This book is ideal for business leaders, investors, and strategy professionals studying corporate spin-offs, portfolio transformation, and resilience through economic cycles. It will also appeal to scientists and executives in the life sciences, diagnostics, and analytical instrumentation industries who want to understand the competitive landscape and innovation history of a market leader. Students of business history and organizational culture will find a rich case study in adapting the 'HP Way' for a specialized, modern scientific enterprise.